# Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

> **NCT03149120** · PHASE2 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Soft Tissue Sarcomas

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT03149120
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08
- **Primary completion:** 2017-08-17
- **Final completion:** 2022-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patient enrolled as new similar study will be in system within 3 months
- **Last updated:** 2017-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149120, "Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03149120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*